3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Mesothelioma, Malignant
46
Mesothelioma
40
Carcinoma, Non-Small-Cell Lung
13
Advanced Solid Tumors
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Solitary Fibrous Tumor, Pleural
5
Advanced Solid Tumor
4
Lung Neoplasms
3
Solid Tumors
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Unspecified Adult Solid Tumor
1
Thymus Neoplasms
1
Thymoma
1
Solid Tumor Cancer
1
Solid Tumor
1
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Interventions
amatuximab
1
Pemetrexed
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Severe combined immunodeficiency with sensitivity to ionizing radiation
×
Pemetrexed
×
Other solid neoplasm
×
Clear all
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts